Dana dhuwit diétung saben saham ymabs.com (YMAB)

Y-mAbs Therapeutics revenues are based on the commercialization of Danyelza and the development of radioimmunotherapy. Actual cash per share reflects liquidity dynamics, with the indicator standing at 1.38. The company develops life-saving treatments for rare pediatric tumors, complementing its strategy with targeted licensing of distribution rights for its antibodies across various global regions.
Rincian metrik komprehensif lan analitis Y-mAbs Corp (YMAB)

This indicator reflects the volume of liquid assets per common share, allowing for an assessment of the real capital cushion and the investor's protection against bankruptcy. Analyzing the cash per share trend confirms the financial stability of Y-mAbs Therapeutics (YMAB), whose exceptional pricing power in the neuroblastoma therapy segment ensures a steady cash flow and high business autonomy.